Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

^68Ga-grazytracer PET for In Vivo Visualization of Immune Cell Effector Functions

A legfontosabb adatok

Ki végzi
Peking University Third Hospital
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
80 fő, tervezett
Kezdés
2026. jún. 1.
Várható befejezés
2028. dec.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • ^68Ga-grazytracer PET/CT
A regiszteradat frissítve
2026. november 13.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Egyéb feltételek

  • **Inclusion Criteria:**
  • Age ≥18 years, regardless of sex
  • Ability to understand the study objectives and provide written informed consent
  • Cancer cohort:
  • Patients with a confirmed diagnosis of malignancy who are scheduled to receive systemic anticancer treatment
  • Patients who have not previously received immunotherapy
  • Autoimmune disease cohort:
  • Patients with a confirmed diagnosis of an autoimmune disease, such as systemic sclerosis or systemic lupus erythematosus, with evidence of immune-mediated inflammation
  • Patients who are scheduled to receive or are currently receiving immunomodulatory therapy; **Exclusion Criteria:**
  • Pregnant or breastfeeding women
  • Patients with severe cardiac, hepatic, renal, or other major organ dysfunction who are considered unsuitable for study participation by the investigator
  • Patients unable to tolerate PET/CT imaging or complete the required follow-up assessments
  • Patients with any other condition that, in the investigator's judgment, makes them unsuitable for participation in the study

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a prospective, single-center, exploratory clinical study designed to evaluate the feasibility, safety, and clinical utility of \^68Ga-grazytracer positron emission tomography (PET) for noninvasive in vivo visualization of immune cell effector function in patients with cancer and autoimmune diseases. \^68Ga-grazytracer is a granzyme B (GZMB)-targeted PET radiotracer developed to visualize cytotoxic immune activation.

A teljes eredeti leírásKevesebb

Approximately 60-80 adult participants will be enrolled in two study cohorts: (1) patients with malignant tumors who are scheduled to receive systemic anticancer therapy, including immune checkpoint inhibitors, CAR-T cell therapy, chemotherapy, radiotherapy, targeted therapy, or combination therapy; and (2) patients with autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, and immune myocarditis, who are receiving or planning to receive immunomodulatory treatment.

Participants will undergo \^68Ga-grazytracer PET/CT imaging before treatment initiation and again during the predefined treatment period. Imaging findings, including tracer uptake and semiquantitative parameters (e.g., SUVmax and target-to-background ratio), will be analyzed together with clinical outcomes, laboratory findings, disease activity assessments, and follow-up data.

The primary objectives are to evaluate the safety and tolerability of \^68Ga-grazytracer PET imaging and to investigate the association between GZMB-targeted PET imaging and treatment response in patients with cancer, disease activity and organ involvement in autoimmune diseases, and therapeutic response to immunomodulatory treatment. This study aims to provide preliminary evidence supporting the use of \^68Ga-grazytracer PET as a molecular imaging biomarker for noninvasive assessment of immune effector function in cancer and autoimmune diseases.

A vizsgálat csoportja

  • ^68Ga-grazytracer PET ImagingA vizsgált kezelés

    All enrolled participants will undergo \^68Ga-grazytracer PET/CT imaging according to the study protocol for noninvasive assessment of immune cell effector function. Participants include patients with cancer and autoimmune diseases. PET/CT imaging will be performed before treatment initiation and during the predefined treatment period according to the study protocol. Imaging findings will be correlated with clinical characteristics, treatment response, and disease activity.

    Kezelés: ^68Ga-grazytracer PET/CT

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
In Vivo Visualization of Immune Cell Effector Functions Using ^68Ga-grazytracer PET: An Exploratory Study of Cancer and Autoimmune Diseases
A regiszteradat frissítve
2026. november 13.